
News|Articles|December 1, 2001
Bioterror response to alter pharmaceutical development and marketing
Uncle Sam is poised to authorize more than $1 billion to buy medicines and vaccines for the national pharmaceutical stockpile, and federal agencies are gearing up to spend millions more on research related to infectious disease. In response, the pharmaceutical industry is assessing how these developments may alter the way it does business.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transforming care through social determinants of health
2
Why MASH patients need a clearer path forward
3
Prior authorization isn't broken. It's unmeasured
4
FDA approves Lumvoa, first TED therapy labeled for both active and chronic disease
5































